JP2011513501A5 - - Google Patents

Download PDF

Info

Publication number
JP2011513501A5
JP2011513501A5 JP2010550880A JP2010550880A JP2011513501A5 JP 2011513501 A5 JP2011513501 A5 JP 2011513501A5 JP 2010550880 A JP2010550880 A JP 2010550880A JP 2010550880 A JP2010550880 A JP 2010550880A JP 2011513501 A5 JP2011513501 A5 JP 2011513501A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
menadione
maintain
water
sufficient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010550880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513501A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/037041 external-priority patent/WO2009114745A1/en
Publication of JP2011513501A publication Critical patent/JP2011513501A/ja
Publication of JP2011513501A5 publication Critical patent/JP2011513501A5/ja
Pending legal-status Critical Current

Links

JP2010550880A 2008-03-13 2009-03-13 局所使用のためのビタミンｋ類似体製剤 Pending JP2011513501A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6921808P 2008-03-13 2008-03-13
US20493909P 2009-01-13 2009-01-13
PCT/US2009/037041 WO2009114745A1 (en) 2008-03-13 2009-03-13 Formulations of vitamin k analogs for topical use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014218037A Division JP2015042658A (ja) 2008-03-13 2014-10-27 局所使用のためのビタミンｋ類似体製剤

Publications (2)

Publication Number Publication Date
JP2011513501A JP2011513501A (ja) 2011-04-28
JP2011513501A5 true JP2011513501A5 (enExample) 2013-05-09

Family

ID=40677542

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010550880A Pending JP2011513501A (ja) 2008-03-13 2009-03-13 局所使用のためのビタミンｋ類似体製剤
JP2014218037A Pending JP2015042658A (ja) 2008-03-13 2014-10-27 局所使用のためのビタミンｋ類似体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014218037A Pending JP2015042658A (ja) 2008-03-13 2014-10-27 局所使用のためのビタミンｋ類似体製剤

Country Status (7)

Country Link
US (2) US8815953B2 (enExample)
EP (1) EP2265255A1 (enExample)
JP (2) JP2011513501A (enExample)
KR (1) KR20110004382A (enExample)
AU (1) AU2009223158B2 (enExample)
CA (1) CA2718262A1 (enExample)
WO (1) WO2009114745A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005989A1 (en) * 2008-07-09 2010-01-14 Edison Pharmaceuticals, Inc. Dermatological compositions with anti-aging and skin even-toning properties
WO2010014361A1 (en) * 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Naphthoquinone compositions with anti-aging, anti- inflammatory and skin even-toning properties
EP2477510B1 (en) 2009-09-14 2018-03-07 Nestec S.A. Nutritional compositions for modulating inflammation including exogenous vitamin k2
ITPD20100090A1 (it) * 2010-03-22 2011-09-23 Sanitas Farmaceutici S R L Formulazione topica per il trattamento di eruzioni cutanee, in particolare conseguenti a trattamenti con farmaci anti egfr
JP2013538799A (ja) * 2010-08-06 2013-10-17 アンペア ライフ サイエンシーズ，インコーポレイテッド ビタミンｋを用いたミトコンドリア病の処置
JP5062922B2 (ja) 2011-02-14 2012-10-31 株式会社Ｊ−オイルミルズ 皮膚コラーゲン産生促進剤
US9421297B2 (en) 2014-04-02 2016-08-23 Adhezion Biomedical, Llc Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides
EP3694491A1 (en) 2017-10-10 2020-08-19 Capsugel Belgium NV Gelling multiparticulates
TW201927292A (zh) 2017-12-13 2019-07-16 大陸商上海小午醫藥科技有限公司 一種用於預防或治療與ｅｇｆｒ被抑制相關疾病的方法
TW201943428A (zh) 2018-04-16 2019-11-16 大陸商上海岸闊醫藥科技有限公司 預防或治療腫瘤療法副作用的方法
WO2020067663A1 (ko) * 2018-09-28 2020-04-02 주식회사 엘지생활건강 피부 턴오버 촉진 및 멜라닌 배출 촉진용 조성물
EP4252844A3 (en) * 2019-04-17 2023-12-06 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294852A (en) * 1973-11-01 1981-10-13 Johnson & Johnson Skin treating compositions
DE3060165D1 (en) * 1979-03-08 1982-03-11 Hoffmann La Roche Process for the stereospecific preparation of compounds of the vitamin k1- and k2-series, as well as new starting materials for the process
JPS6025918A (ja) * 1983-07-25 1985-02-08 Ajinomoto Co Inc 脂溶性薬物含有水性液
DE3406497A1 (de) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
DE3514724A1 (de) 1985-04-24 1986-10-30 Albin F. Dr. 4200 Oberhausen Jereb Salbe zur verbeugung und behandlung von augen- und hauterkrankungen
JPS62294636A (ja) * 1986-05-21 1987-12-22 Eisai Co Ltd ２−メチル−１，４−ナフトキノンの製造法
US5180747A (en) * 1989-02-28 1993-01-19 Nisshin Flour Milling Co., Ltd. Stabilized fat-soluble vitamin compositions
ZA902066B (en) 1989-04-14 1990-12-28 Minnesota Mining & Mfg Solid gel external drug delivery system
US4966779A (en) * 1989-12-21 1990-10-30 Basf Corporation Stable, water miscible emulsion comprising a fat-soluble vitamin
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5155031A (en) * 1990-06-07 1992-10-13 Posner Barry I Use of pervanadate as an inhibitor of phosphotyrosine phosphatase
FR2672288B1 (fr) * 1991-02-06 1993-04-23 Oreal Nouveaux amides dipeptidiques derivant de la glycyl-serine, utilisables, notamment dans des compositions cosmetiques, pharmaceutiques ou alimentaires.
DE4141351A1 (de) * 1991-12-14 1993-06-17 Basf Ag Stabile pulverfoermige vitamin- und/oder carotinoid-praeparate und verfahren zu deren herstellung
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5510391A (en) * 1993-10-22 1996-04-23 Mayapple Holdings, Llc Method of treating blood vessel disorders of the skin using vitamin K
FR2719219B1 (fr) * 1994-05-02 1996-06-21 Rocher Yves Biolog Vegetale Composition cosmétique ou pharmaceutique à usage topique comprenant des vésicules lipidiques.
US5637741A (en) * 1994-09-27 1997-06-10 Kuraray Co., Ltd. Process for producing 2-methyl-1,4-naphthoquinone
AU2804297A (en) 1996-04-22 1997-11-12 Advanced Polymer Systems Inc. Method of and composition for treating disorders of the skin using vitamin k
KR0178456B1 (ko) * 1996-04-25 1999-05-15 김흥기 2-메틸-1,4-나프토퀴논(비타민 k3)의 제조방법
SE9601665D0 (sv) * 1996-04-30 1996-04-30 Bioglan Ab Biologically active composition
US6110891A (en) * 1996-06-21 2000-08-29 Alizyme Therapeutics Ltd. Lectin compositions and uses thereof
DE19642359A1 (de) * 1996-10-14 1998-04-16 Basf Ag Stabile Emulsionen und Trockenpulver von Mischungen fettlöslicher Vitamine, deren Herstellung und Verwendung
US5916749A (en) * 1996-12-13 1999-06-29 Incyte Pharmaceuticals, Inc. Human phosphatase inhibitor protein
US6426078B1 (en) * 1997-03-17 2002-07-30 Roche Vitamins Inc. Oil in water microemulsion
US6599513B2 (en) * 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
EP1027045A4 (en) * 1997-10-31 2004-12-08 Arch Dev Corp METHODS AND COMPILATIONS FOR REGULATING S-ALPHA REDUCTASE ACTIVITY
US6696484B2 (en) * 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
US6013665A (en) * 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
CA2329160A1 (en) 1998-06-11 1999-12-16 University Of Medicine & Dentistry Of New Jersey Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
US6207176B1 (en) * 1998-09-14 2001-03-27 National Starch And Chemical Investment Holding Corporation Starch based adhesives for skin cleaning tape
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6187822B1 (en) * 1999-06-11 2001-02-13 University Of Medicine & Dentistry Of Nj Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
US6524594B1 (en) * 1999-06-23 2003-02-25 Johnson & Johnson Consumer Companies, Inc. Foaming oil gel compositions
US7927612B2 (en) * 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
DE10003786A1 (de) 2000-01-28 2001-08-02 Merck Patent Gmbh Galenische Formulierung
CA2401340A1 (en) * 2000-02-28 2001-09-07 The University Of British Columbia Compositions and methods for the treatment of inflammatory disease using topoisomerase inhibitors
WO2001067896A2 (de) 2000-03-17 2001-09-20 Basf Aktiengesellschaft Verfahren zur herstellung öliger suspensionen wasserlöslicher vitamine
WO2001070255A2 (en) * 2000-03-20 2001-09-27 Pfizer Products, Inc. Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
US20040047852A1 (en) * 2001-03-02 2004-03-11 Kennedy Thomas Preston Method of treating cancer
US20020040011A1 (en) 2000-06-01 2002-04-04 Brown Dennis M. Naphthoquinone compositions and uses thereof
PL342071A1 (en) 2000-08-18 2001-02-12 Szolomicka Orfinger Irena Cosmetic cream
GB0022079D0 (en) 2000-09-08 2000-10-25 Inst Of Molecul & Cell Biology Novel protein tyrosine phosphatase inhibitor
US6660306B2 (en) * 2000-10-12 2003-12-09 Mickey L. Peshoff Wound healing compound
US7094431B2 (en) * 2000-10-12 2006-08-22 Mickey L. Peshoff Method of healing skin wounds in mammals and a composition therefor
US6774100B2 (en) * 2000-12-06 2004-08-10 Imaginative Research Associates, Inc. Anhydrous creams, lotions and gels
DE60009521T2 (de) 2000-12-15 2005-03-03 Dr. Patrick Franke Hypoallergenes nichtreizendes Hautpflegemittel
IL156411A0 (en) * 2000-12-15 2004-01-04 Franke Patrick Hypoallergenic and non-irritant skin care formulations
US6780439B2 (en) * 2001-03-06 2004-08-24 J. Ronald Wilk Wound treatment solution and method for using same
US6579994B2 (en) * 2001-03-29 2003-06-17 Council Of Scientific And Industrial Research Process for preparation of 2-Methyl-1,4-naphthoquinone
US6812220B2 (en) 2001-08-29 2004-11-02 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
US20070238697A1 (en) * 2001-08-29 2007-10-11 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
US8156471B2 (en) * 2001-11-09 2012-04-10 Oracle International Corporation Multi-language execution method
US7405188B2 (en) * 2001-12-12 2008-07-29 Wsp Chemicals & Technology, Llc Polymeric gel system and compositions for treating keratin substrates containing same
EP1469860A4 (en) 2002-01-24 2005-09-07 Yissum Res Dev Co ANTICANCER COMBINATION AND USE THEREOF
JP2003226639A (ja) * 2002-01-31 2003-08-12 Hisamitsu Pharmaceut Co Inc 神経成長因子活性増強剤としてのビタミンｋ類を含む医薬組成物およびその使用
US20030170187A1 (en) * 2002-03-01 2003-09-11 Alfred Marchal Skin treatments containing nano-sized vitamin K
AU2003228974A1 (en) 2002-05-07 2003-11-11 Memgen Corporation Method of and apparatus for forming three-dimensional structures
GB0212749D0 (en) 2002-06-01 2002-07-10 Boots Co Plc Personal care compositions
GB0220182D0 (en) 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
WO2004098569A1 (en) * 2003-04-18 2004-11-18 Northeastern University Micelle delivery system loaded with a pharmaceutical agent
US7320797B2 (en) * 2003-08-29 2008-01-22 Bioderm Research Antiaging cosmetic delivery systems
EP1667659A1 (en) 2003-09-30 2006-06-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
US20050092969A1 (en) * 2003-10-08 2005-05-05 Kaneka Corporation Method of stabilizing compound having quinone skeleton and stabilized composition
JP2005206521A (ja) 2004-01-22 2005-08-04 Nippon Menaade Keshohin Kk 抗菌剤
KR20060002239A (ko) * 2004-07-01 2006-01-09 삼성전자주식회사 레이저 출력 제어장치
EP1796656A2 (en) 2004-09-17 2007-06-20 Oystershell NV Composition for inhibiting or preventing the formation of a biofilm
CA2583315A1 (en) 2004-10-06 2006-06-01 Tiltan Pharma Ltd. Method and composition for enhancing anti-angiogenic therapy
WO2006107827A1 (en) 2005-04-05 2006-10-12 Creighton University Skin bonding process
ES2358528T3 (es) 2005-04-15 2011-05-11 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Vitamina k para la prevención y el tratamiento de una erupción cutánea secundaria a una terapia anti-egfr.
US20060275504A1 (en) * 2005-06-07 2006-12-07 Tty Biopharm Company Limited Methods and compositions for augmenting cancer chemotherapeutic agents
US20070025950A1 (en) * 2005-07-28 2007-02-01 Elson Melvin L Composition and method for treating cellulite
US7252816B1 (en) * 2006-03-29 2007-08-07 Dow Pharmaceutical Sciences Topical acne vulgairs medication with a sunscreen
WO2007147128A2 (en) 2006-06-16 2007-12-21 Summa Health System Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
WO2008004231A1 (en) 2006-07-07 2008-01-10 Tiltan Pharma Ltd. Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent

Similar Documents

Publication Publication Date Title
JP2011513501A5 (enExample)
JP7201660B2 (ja) 皮膚の弛緩と身体の輪郭を改善するための組成物および方法
ES2260834T3 (es) Uso de retinoides a altas dosis para el tratamiento de piel fotodañada.
CL2012003229A1 (es) Formulación farmacéutica para aplicación tópica en la piel que comprende una emulsión de aceite en agua y el compuesto (r)-3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrilo, inhibidor de jak1/jak2; método para tratar un trastorno de la piel; y su uso en el tratamiento de un trastorno de la piel.
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
KR102127022B1 (ko) 레티노이드를 함유하는 수중유 에멀전 유형 국소용 조성물
RU2015115723A (ru) Кетопрофеновая композиция для местного применения
WO2009053741A3 (en) Novel formulation
ES2829524T3 (es) Composiciones de limpieza
JP2015042658A (ja) 局所使用のためのビタミンｋ類似体製剤
WO2005027977A2 (en) Diclofenac compositions for the treatment of skin disorders
CN103002863B (zh) 利用多种活性物质改善色素沉着斑点外观的方法
CN103948518A (zh) 含有己脒定和维a类化合物的用于改善皮肤的组合物
KR101939453B1 (ko) 자극이 감소된 화장 조성물
AR064262A1 (es) Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato
SG10201908690WA (en) Novel method of use and compositions
US9402823B2 (en) Ingenols for treating seborrheic keratosis
CN102844026A (zh) 真菌甲治疗组合物
JP5895244B2 (ja) 機能性化粧水
KR20240134863A (ko) 심부 진피 약물 전달을 위한 스피로노락톤의 약학 조성물
US20130197089A1 (en) Compositions for the treatment of actinic keratosis
JP2013209334A (ja) 表皮肥厚促進剤
JP5252765B2 (ja) 皮脂産生抑制剤及び皮脂腺発達抑制剤、並びに、皮膚外用剤
BE1021016B1 (nl) Samenstelling voor de behandeling van nagelziektes en gebruik
JP5985346B2 (ja) 皮膚化粧料